Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tolebrutinib
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tolebrutinib gets US Priority Review for Multiple Sclerosis
Details : SAR442168 (tolebrutinib) is an investigational brain-penetrant and bioactive BTK inhibitor. Tolebrutinib is being evaluated for relapsing forms of MS, nrSPMS and PPMS.
Product Name : SAR442168
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 25, 2025
Lead Product(s) : Tolebrutinib
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolebrutinib
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tolebrutinib Receives Breakthrough Therapy Status From FDA for Secondary MS
Details : SAR442168 (tolebrutinib) is an investigational brain-penetrant and bioactive BTK inhibitor. Tolebrutinib is being evaluated for relapsing forms of MS, nrSPMS and PPMS.
Product Name : SAR442168
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 12, 2024
Lead Product(s) : Tolebrutinib
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Frexalimab Ph 2 Data Showed Red of Key Biomarker of Nerve Cell Damage in Relapsing MS
Details : SAR441344 (frexalimab), a first-in-class, second generation anti-CD40 ligand monoclonal antibody, which is being evaluated for the treatment of relapsing multiple sclerosis.
Product Name : SAR441344
Product Type : Antibody
Upfront Cash : Inapplicable
June 28, 2024
Sanofi's Riliprubart Shows Promise in CIDP Treatment
Details : SAR445088 (riliprubart) is a potential first-in-class, IgG4 humanized antibody that selectively inhibits activated C1s. It is being evaluated for chronic inflammatory demyelinating polyneuropathy.
Product Name : SAR445088
Product Type : Antibody
Upfront Cash : Inapplicable
June 25, 2024
New Frexalimab Phase 2 Data Support High Sustained Efficacy in Multiple Sclerosis
Details : SAR441344 (frexalimab) is a second-generation anti-CD40L antibody under investigation for relapsing and non-relapsing secondary progressive MS.
Product Name : SAR441344
Product Type : Antibody
Upfront Cash : Inapplicable
April 16, 2024
Lead Product(s) : Tolebrutinib
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sanofi MS Drug Tolebrutinib Misses Goal in Relapsing Disease Trials
Details : SAR442168 (tolebrutinib) is an investigational brain-penetrant and bioactive BTK inhibitor. Tolebrutinib is being evaluated for relapsing forms of MS, nrSPMS and PPMS.
Product Name : SAR442168
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 09, 2024
Lead Product(s) : Tolebrutinib
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SAR441344 (frexalimab) is a novel monoclonal antibody that is thought to block the costimulatory CD40/CD40L and investigational product relapsing multiple sclerosis.
Product Name : SAR441344
Product Type : Antibody
Upfront Cash : Inapplicable
May 31, 2023
Lead Product(s) : Tolebrutinib
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SAR442168 (tolebrutinib) is an investigational brain-penetrant and bioactive BTK inhibitor that achieves CSF concentrations predicted to modulate B lymphocytes and microglial cells. Tolebrutinib is being evaluated for relapsing forms of MS, nrSPMS and PP...
Product Name : SAR442168
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 23, 2023
Lead Product(s) : Tolebrutinib
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolebrutinib
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tolebrutinib Clinical Trial Program Update
Details : SAR442168 (tolebrutinib) is an investigational brain-penetrant and bioactive Bruton’s tyrosine kinase (BTK) inhibitor that achieves CSF concentrations sufficient to modulate B lymphocytes and microglial cells.
Product Name : SAR442168
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 08, 2022
Lead Product(s) : Tolebrutinib
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolebrutinib
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Patient Enrollment of Phase III Tolebrutinib Trials Paused in the U.S.
Details : SAR442168 (tolebrutinib) is an investigational brain-penetrant and bioactive Bruton’s tyrosine kinase (BTK) inhibitor that achieves CSF concentrations needed for targeting B lymphocytes and microglial cells.
Product Name : SAR442168
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 30, 2022
Lead Product(s) : Tolebrutinib
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
